Mimedx (MDXG) Net Margin (2011 - 2026)

Mimedx (MDXG) reported Net Margin of 18.41% for Q1 2026, down 329.95% sequentially from 8.01% in Q4 2024.

Mimedx (MDXG) Net Margin (2011 - 2026) Analysis & Trends

Mimedx (MDXG) has 15 years of Net Margin data on file, last reported at 18.41% in Q1 2026.

For the quarter ending Q1 2026, Net Margin changed N/A year-over-year to 18.41%; the trailing twelve-month figure through Mar 2026 stood at 2.79% (down 1214.0% YoY), and the FY2025 full-year result was 11.6%, down 43.0% from the prior year.
Net Margin eased to 18.41% in Q1 2026, from 8.01% in the prior quarter.
In the past five years, Net Margin ranged from a high of 51.63% in Q4 2023 to a low of 20.5% in Q1 2022.
A 4-year average of 3.94% and a median of 8.65% in 2023 frame the typical range for Net Margin.
Across the five-year window, Net Margin jumped 4069 bps in 2023 and slumped 4362 bps in 2024, its largest moves.
Tracing MDXG's Net Margin over 4 years: stood at 10.94% in 2022, then soared by 372 bps to 51.63% in 2023, then plunged by 84 bps to 8.01% in 2024, then slumped by 330 bps to 18.41% in 2026.
Business Quant data shows MDXG's Net Margin at 18.41% in Q1 2026, 8.01% in Q4 2024, and 9.37% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mimedx	615.09 Mn	455.31 Mn	41.62 Mn	-18.41%

Download Data